We use third-party cookies to provide support. By continuing to browse this website,
you accept our privacy policy.
Glaukos Corp
2 own
7 watching
Current Price
$68.26
$0
(0%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Market Capitalization
3,272.45M
52-Week High
70.05
52-Week Low
40.45
Average Volume
0.15M
Dividend Yield
--
P/E Ratio
--
Market Capitalization3,272.45M52-Week High70.0552-Week Low40.45Average Volume0.15MDividend Yield--P/E Ratio--What does the Glaukos Corp do?
Glaukos Corporation, an ophthalmic medical technology company, focuses on the development and commercialization of products and procedures designed to treat glaucoma. It offers iStent, a micro-bypass stent for insertion in conjunction with cataract surgery for the reduction of intraocular pressure in adult patients with mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Inject trabecular micro-bypass stent that allows the surgeon to inject stents into various trabecular meshwork locations through a single corneal entry with the goal of achieving intraocular pressure reduction; iStent Supra suprachoroidal micro-bypass stent, which is designed to reduce intraocular pressure by accessing the suprachoroidal space in the eye; and iDose, a targeted injectable drug delivery implant that is designed to be pre-loaded into a small gauge needle and injected into the eye through a self-sealing corneal needle penetration. It markets its products through direct sales force in the United States and internationally, as well as through distribution partners in Europe, the Asia Pacific, and internationally. Glaukos Corporation was founded in 1998 and is headquartered in San Clemente, California.
Read More
How much money does Glaukos Corp make?
News & Events about Glaukos Corp.
Zolmax
1month ago
Shares of Glaukos Co. (NYSE:GKOS Get Rating) have been given a consensus rating of Hold by the eleven ratings firms that are presently covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, four have given a hold recommendation and five have ...
Zolmax
1month ago
Shares of Glaukos Co. (NYSE:GKOS Get Rating) have been assigned an average recommendation of Hold from the eleven analysts that are currently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, four have given a hold ...
Ticker Report
1month ago
Shares of Glaukos Co. (NYSE:GKOS Get Rating) have received an average rating of Hold from the eleven ratings firms that are covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and five ...
Ticker Report
1month ago
Glaukos Co. (NYSE:GKOS Get Rating) has been given an average rating of Hold by the eleven ratings firms that are presently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and five have...
Business Wire
1month ago
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release first quarter 2023 financial results after the market close on Wednesday, May 3, 2023. The...
Frequently Asked Questions
Frequently Asked Questions
What is Glaukos Corp share price today?
Can Indians buy Glaukos Corp shares?
How can I buy Glaukos Corp shares from India?
Can Fractional shares of Glaukos Corp be purchased?
What are the documents required to start investing in Glaukos Corp stocks?
What is today’s traded volume of Glaukos Corp?
What is today’s market capitalisation of Glaukos Corp?
What is the 52-Week High and Low Range of Glaukos Corp?
What percentage is Glaukos Corp down from its 52-Week High?
What percentage is Glaukos Corp up from its 52-Week Low?
Current Price
$68.26
$0
(0%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.